Congressional Report: FDA Broke Own Protocols in Approving Biogen Alzheimer's Drug
The FDA failed to adhere to its own guidance and internal practices during the approval process for Biogen's Alzheimer's drug Aduhelm, which was 'rife with irregularities,' a congressional report showed on Thursday.
Reuters Health Information
source https://www.medscape.com/viewarticle/986319?src=rss
Reuters Health Information
source https://www.medscape.com/viewarticle/986319?src=rss
Comments
Post a Comment